Cilag AG has inaugurated a new microbiology laboratory building in Greater Zurich, which will perform quality control for products manufactured at its facility there. Cilag, a pharmaceutical company that belongs to Johnson & Johnson, invested CHF 20 million in the building.

Cibag weiht neues Labor ein
Image credit: Cilag.


Cilag AG inaugurated its new microbiology laboratory building at its site in Schaffhausen on Thursday, one year after it laid the first foundation stone.

The new building features 2,000 square meters of state-of-the-art laboratories and modern offices. The lab will conduct quality control of products manufactured at its site in Schaffhausen, upgrading the site’s existing biotech labs.

Cilag will move into the new lab in stages through to May 2020 in order to prevent any disruptions to its operations. An inspection center on the ground floor will also be established in the coming months, which will be responsible for conducting audits with health authorities from around the world. Cilag invested around CHF 20 million in the new building and calls its completion “an important step in the ongoing strategic development of our site”.

A member of the Johnson & Johnson group, Cilag produces pharmaceutical ingredients and products, which are sold under the Janssen brand. It employs around 1,300 staff, making it one of the largest manufacturers in the Swiss pharmaceutical industry.

Contact us

Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center? Give us a call or drop us a line. 

+41 44 254 59 59